Skip to main content
NIH funding notice PAR-22-140

Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R21 Clinical Trial Not Allowed)

Closed on November 18, 2024.

Posted
March 18, 2022
Close date
November 18, 2024
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $717,420 in first-year total cost, median $358,710.

Most frequent study sections

  1. Radiation Therapeutics and Biology Study Section[RTB]2

Most frequent institutions

  1. FRED HUTCHINSON CANCER CENTER1
  2. HUNTER COLLEGE1
Competing awards under PAR-22-140 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2023Targeting DNA Mismatches for Auger Electron Radiotherapy1R21CA280595-01A1HUMM, JOHN LZEGLIS, BRIAN MATTHEWHUNTER COLLEGE, NY$457,607RTB
2023Selective Radionuclide Delivery for Precise Bone Marrow Niche Alterations1R21CA283589-01OROZCO, JOHNNIE JOSETERMINI, CHRISTINA MARIEFRED HUTCHINSON CANCER CENTER, WA$259,813RTB

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

PAR-22-140: Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R21 Clinical Trial Not Allowed) | ScienceDex | ConductScience